Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 19/20 | 0.47 |
| ▸ | PIK3CA | P42336 | 16/20 | 0.47 |
| ▸ | PIK3CB | P42338 | 15/20 | 0.47 |
| ▸ | PIK3CG | P48736 | 15/20 | 0.47 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1088509 | 0.95 | PIK3CD (0.46) | PIK3CDPIK3CAPIK3CBPIK3CGPIK3R1 | |
| SCHEMBL1088662 | 0.92 | PIK3CD (0.49) | PIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL1180854 | 0.86 | PIK3CA (0.46) | PIK3CAPIK3CB | |
| SCHEMBL190918 | 0.86 | PIK3CA (0.40) | PIK3CDPIK3CAPIK3CBPIK3CGPIK3R1 | |
| SCHEMBL994245 | 0.85 | PIK3CA (0.48) | PIK3CDPIK3CAPIK3CBPIK3CGPIK3R1 | |
| SCHEMBL1088489 | 0.85 | PIK3CA (0.52) | PIK3CDPIK3CAPIK3CBPIK3CGPIK3R1 | |
| SCHEMBL1088653 | 0.85 | PIK3CA (0.48) | PIK3CDPIK3CAPIK3CBPIK3CGPIK3R1 | |
| SCHEMBL1087184 | 0.85 | PIK3CD (0.46) | PIK3CDPIK3CAPIK3CBPIK3CGPIK3R1 | |
| SCHEMBL1088023 | 0.84 | PIK3CA (0.48) | PIK3CDPIK3CAPIK3CBPIK3CGPIK3R1 | |
| SCHEMBL1088340 | 0.83 | PIK3CA (0.50) | PIK3CDPIK3CAPIK3CBPIK3CGPIK3R1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1812445-B1 | PHARMACEUTICAL COMPOUNDS | PIRAMED LTD (GB) | 2015-12-30 | — | — | EP | disclosed |
| EP-1812444-B1 | PHARMACEUTICAL COMPOUNDS | PIRAMED LTD (GB) | 2015-08-26 | — | — | EP | disclosed |
| US-8946217-B2 | Pharmaceutical compounds | F. HOFFMANN-LA ROCHE AG (CH) | 2015-02-03 | — | — | US | disclosed |
| US-20140294946-A1 | PHARMACEUTICAL COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2014-10-02 | — | — | US | disclosed |
| US-20130317017-A1 | PHARMACEUTICAL COMPOUNDS | F. HOFFMAN-LA ROCHE AG (CH) | 2013-11-28 | — | — | US | disclosed |
| US-20120258966-A1 | PHARMACEUTICAL COMPOUNDS | F. HOFFMAN-LA ROCHE AG (CH) | 2012-10-11 | — | — | US | disclosed |
| US-8153629-B2 | Pharmaceutical compounds | F. HOFFMANN-LA ROCHE AG (CH) | 2012-04-10 | — | — | US | disclosed |
| US-8101607-B2 | Pharmaceutical compounds | F. HOFFMAN-LA ROCHE AG (CH) | 2012-01-24 | — | — | US | disclosed |
| US-20100280027-A1 | PHARMACEUTICAL COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2010-11-04 | — | — | US | disclosed |
| US-20100234370-A1 | PHARMACEUTICAL COMPOUNDS | PIRAMED LIMITED (GB) | 2010-09-16 | — | — | US | disclosed |
| US-7776856-B2 | Pharmaceutical compounds | F. HOFFMAN-LA ROCHE AG (CH) | 2010-08-17 | — | — | US | disclosed |
| US-7750002-B2 | Pharmaceutical compounds | PIRAMED LIMITED (GB) | 2010-07-06 | — | — | US | disclosed |
| US-20090131429-A1 | Pharmaceutical compounds | F. HOFFMANN-LA ROCHE AG (CH) | 2009-05-21 | — | — | US | disclosed |
| US-20080207611-A1 | Pharmaceutical compounds | PLRAMED LIMITED (GB) | 2008-08-28 | — | — | US | disclosed |
| EP-1812445-A1 | PHARMACEUTICAL COMPOUNDS | Piramed Limited (GB) | 2007-08-01 | — | — | EP | disclosed |
| WO-2006046031-A1 | PHARMACEUTICAL COMPOUNDS | PIRAMED LIMITED (GB) | 2006-05-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140294946-A1 | PHARMACEUTICAL COMPOUNDS | PIK3CA, JAK2, PIK3R1 | PIK3CD 12/4885PIK3CA 1/4885PIK3CB 14/4885 |
| US-20100234370-A1 | PHARMACEUTICAL COMPOUNDS | PIK3CA, JAK2, PIK3R1 | PIK3CD 12/4885PIK3CA 1/4885PIK3CB 14/4885 |
| US-20100280027-A1 | PHARMACEUTICAL COMPOUNDS | PIK3CA, PIK3C2B, PIK3C2A | PIK3CD 4/4885PIK3CA 1/4885PIK3CB 5/4885 |
| US-20090131429-A1 | Pharmaceutical compounds | PIK3CA, PIK3C2B, PIK3CD | PIK3CD 3/4885PIK3CA 1/4885PIK3CB 12/4885 |
| US-20080207611-A1 | Pharmaceutical compounds | PIK3CA, JAK2, PIK3R1 | PIK3CD 12/4885PIK3CA 1/4885PIK3CB 14/4885 |
| US-20120258966-A1 | PHARMACEUTICAL COMPOUNDS | PIK3CA, JAK2, PIK3R1 | PIK3CD 12/4885PIK3CA 1/4885PIK3CB 14/4885 |
| US-20130317017-A1 | PHARMACEUTICAL COMPOUNDS | PIK3CA, JAK2, PIK3R1 | PIK3CD 12/4885PIK3CA 1/4885PIK3CB 14/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.